Name: Latest research reports of Mankind Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Mankind Pharma Ltd.

NSE: MANKIND | BSE: 543904 | ISIN: INE634S01028 | Industry: Pharmaceuticals
| Expensive Performer

2170.0000 -43.90 (-1.98%)

NSE Jan 19, 2026 09:07 AM

Near 52W Low of ₹2090.00

Volume: 538

Mankind Pharma Ltd.

01 Aug 2025

2170.00

-1.98%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. has an average target of 2684.00 from 3 brokers.